Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MEDI6012 in Subjects With Stable Coronary Artery Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women 40 - 75 years old~* History of Stable CAD~* Currently receiving statin as standard of care~Exclusion Criteria:~* Severe angina pectoris symptoms~* High-risk coronary or carotid artery disease that will likely require surgical or percutaneous intervention during the study period~* Hospitalization for heart failure within 12 months prior to screening~* Uncontrolled Hypertension~* Within 6 months prior to screening, a history of ACS or hospitalization for heart failure~* Clinically significant abnormalities in rhythm, conduction or morphology of ECG~* Subjects with transplanted heart, left ventricular assist device, implanted pacemaker, implantable cardioverter defibrillator, or cardiac resynchronization therapy~* Untreated life-threatening ventricular arrhythmias~* History, within 12 months prior to screening, of myocarditis or restrictive pericarditis, or hemodynamically significant valvular hear disease or aortic disease~* Undergone major surgery with in 3 months prior to screening or has planned major surgery during the study period

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- MEDI6012 24 mg IV (Type: EXPERIMENTAL): Participants received a single IV dose of 24 mg MEDI6012 on Day 1.
- MEDI6012 80 mg IV (Type: EXPERIMENTAL): Participants received a single IV dose of 80 mg MEDI6012 on Day 1.
- MEDI6012 240 mg IV (Type: EXPERIMENTAL): Participants received a single IV dose of 240 mg MEDI6012 on Day 1.
- MEDI6012 800 mg IV (Type: EXPERIMENTAL): Participants received a single IV dose of 800 mg MEDI6012 on Day 1.
- MEDI6012 80 mg SC (Type: EXPERIMENTAL): Participants received a single SC dose of 80 mg MEDI6012 on Day 1.
- Placebo Intravenous (IV) (Type: PLACEBO_COMPARATOR): Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.
- MEDI6012 600 mg SC (Type: EXPERIMENTAL): Participants received a single SC dose of 600 mg MEDI6012 on Day 1.
- Placebo Subcutaneous (SC) (Type: PLACEBO_COMPARATOR): Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).